The company’s most advanced compound, SRX246, a treatment for intermittent explosive disorder, will begin phase-two, clinical trials in the first quarter of 2014. Azevan is also developing treatment for anger, aggression and impulse control disorders, which often spring from traumatic brain injury, attention deficit hyperactivity disorder, post-traumatic stress disorder (PTSD) and personality disorders. Read more.
Client & Alumni News
Ben Franklin client Azevan is developing novel treatments for stress, mood and behavioral disorders
The Ben Franklin Technology Partners is an initiative of the Pennsylvania Department of Community and Economic Development and is funded by the Ben Franklin Technology Development Authority.